If I am understanding both your response and the P

If I am understanding both your response and the PR correctly, then this will try to maximize response rates based on the current dose levels. Based on the current overlap period and protocol outside of the density test, I would expect over 90% response rate post virologic failures. I would expect virologic failures to be around what 700 mg currently has of 17%. Response rates for both 350 mg and 525 mg would likely increase or as the density test will show they need a higher dose and get better results. I would guess this results in more 700 mg doses and less at 350 mg and 525 mg, but being specific to each patients should make the results much better. Less random dosing and specific should help with the response rates before taking into count the longer overlap periods.

Hopefully this is a simple process and the protocol is easy to implement for the pivotal trial.

Please do your own due diligence. All my posts and comments are not to be considered investment advice.